In the past week, APVO stock has gone down by -13.54%, with a monthly decline of -0.54% and a quarterly plunge of -37.47%. The volatility ratio for the week is 10.44%, and the volatility levels for the last 30 days are 24.99% for Aptevo Therapeutics Inc The simple moving average for the past 20 days is -8.81% for APVO’s stock, with a -84.94% simple moving average for the past 200 days.
Is It Worth Investing in Aptevo Therapeutics Inc (NASDAQ: APVO) Right Now?
APVO has 36-month beta value of 5.02. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for APVO is 18.50M, and currently, short sellers hold a 6.50% ratio of that float. The average trading volume of APVO on November 19, 2024 was 6.37M shares.
APVO) stock’s latest price update
The stock of Aptevo Therapeutics Inc (NASDAQ: APVO) has increased by 10.15 when compared to last closing price of 0.22.Despite this, the company has seen a loss of -13.54% in its stock price over the last five trading days. accesswire.com reported 2024-11-11 that Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB (“Alligator”) (STO:ATORX)(ATORX) and Aptevo Therapeutics (“Aptevo”) (Nasdaq:APVO) today announced preliminary data from the companies’ Phase 1 trial evaluating the first-in-class bispecific antibody, ALG.APV-527, as monotherapy for the treatment of multiple solid tumor types likely to express tumor antigen 5T4. These data indicate that trial endpoints of adequate exposure, safety, tolerability and biological activity were met.
Analysts’ Opinion of APVO
Piper Jaffray, on the other hand, stated in their research note that they expect to see APVO reach a price target of $6. The rating they have provided for APVO stocks is “Overweight” according to the report published on October 05th, 2017.
APVO Trading at 5.84% from the 50-Day Moving Average
After a stumble in the market that brought APVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.80% of loss for the given period.
Volatility was left at 24.99%, however, over the last 30 days, the volatility rate increased by 10.44%, as shares sank -34.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -35.18% lower at present.
During the last 5 trading sessions, APVO fell by -16.27%, which changed the moving average for the period of 200-days by -96.58% in comparison to the 20-day moving average, which settled at $0.2602. In addition, Aptevo Therapeutics Inc saw -97.02% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APVO
Current profitability levels for the company are sitting at:
- -27.28 for the present operating margin
- 0.65 for the gross margin
The net margin for Aptevo Therapeutics Inc stands at -26.3. The total capital return value is set at -2.66. Equity return is now at value -250.96, with -113.61 for asset returns.
Based on Aptevo Therapeutics Inc (APVO), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at -4.82. The debt to equity ratio resting at 1.09. The interest coverage ratio of the stock is -2.57.
Currently, EBITDA for the company is -28.31 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 1.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.70.
Conclusion
To put it simply, Aptevo Therapeutics Inc (APVO) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
